D-Day Approaches For Bayer’s Asundexian Phase III Plans
Factor XIa Inhibitor Impressive So Far
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.
